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ABSTRACT 
Objective: A rapid and selective high performance liquid chromatography (HPLC) method for estimation of Deferasirox in Human plasma was 
developed and validated. 
Methods: Analyte was recovered by protein precipitation technique and subsequently separated on C18 column (150x4.5 mm, 5µ) by using 
acetonitrile: phosphate buffer pH 3.0(60:40) as mobile phase at a flow rate of 1.0 ml/min at 248 nm.  
Results: The calibration curve was linear over the concentration range 0.4-4.8 µg/ml in human plasma. Within-batch and between-batch precision 
were<15% (at LLOQ<20%) and accuracy was all within 15%. (at LLOQ<20%).  
Conclusion: The developed and validated HPLC method was specific, sensitive and reproducible which can be used for routine drug analysis and 
bioanalysis.  
Keywords: HPLC-UV, Bioanalytical, Deferasirox, Human plasma. 
 
INTRODUCTION 
Deferasirox belongs to the class Antidote. Chemical name is 4-[3, 5-
bis (2-hydroxyphenyl)-1H 1, 2, 4-triazol-1-yl]-benzoic acid.  
 
Deferasirox is an oral iron chelator. Its main use is to reduce 
chronic iron overload in patients who are receiving long term 
blood transfusions for conditions such as beta thalassemia and 
other chronic anemias. Deferasirox is an orally active chelator that 
is selective for iron (as Fe3+). It is a tridentate ligand that binds 
iron with high affinity in a 2:1 ratio. It is not official in any of the 
pharmacopoeia. It is listed in the Merck index 14th edition and 
Martindale the complete drug reference 35th
The mobile phase used was acetonitrile and phosphate buffer (pH 
3.0) (60:40). An isocratic method is developed table-1. Before 
analyses, the mobile phase was filtered through 0.45 μm filter and 
then degassed ultrasonically for 10 min. The analyses were 
conducted at a flow rate of 1.0 ml/min. The eluent was monitored at 
a wavelength of 248 nm for deferasirox. The total run time was 10 
min and injection volume was 20μl. 
 edition [1-3].  
Literature survey revealed that validated HPLC method for the 
quantification of Deferasirox in plasma is not reported [4-10]. For 
the estimation of the drugs present in the biological fluid, HPLC 
method is considered to be more suitable since this is a specific, 
linear, precise, accurate, sensitive and rapid method. In this study, 
we have developed a HPLC-UV method with a protein precipitation 
extraction and improved sensitivity for the determination of 
Deferasirox in plasma and the developed method is validated as per 
regulatory requirements [11]. 
MATERIALS AND METHODS 
Chemicals 
Deferasirox was gifted by Torrent Pharmaceuticals Pvt. Ltd. Gujarat. 
HPLC Grade Solvents (Acetonitrile, Methanol, Water) and Di 
potassium hydrogen phosphate were obtained from Merck 
Specialities Pvt. Ltd., Mumbai and ortho phosphoric acid were from 
S. D. Fine chem. Ltd., Mumbai. 
Instrument 
Younglins Acme 9000 LC system were equipped with a UV detector. 
Chromatographic separations were performed using the 
Phenomenex C18 (150x4.6 mm, 5μ) column and analyzed by LC 
software Autochro-3000. 
Preparation of solutions 
Phosphate buffer was prepared by dissolving approximately 0.34g of 
potassium dihydrogen phosphate in 250 ml of HPLC water and the 
pH was adjusted to 3.0 with acetic acid. 
Preparation of standard 
Deferasirox stock solutions were prepared at a concentration of 1 
mg/ml by dissolving in methanol and the stock solutions were stored 
in the refrigerator. Spiking solutions of deferasirox for the preparation 
of calibration standards and quality control samples were prepared in 
methanol and spiked into the plasma. The calibration curve from 
0.8μg/ml to 4.8μg/ml was generated using six calibration standards at 
the concentrations of 0.8μg/ml (STD 1), 1.6μg/ml (STD 2), 2.4μg/ml 
(STD 3), 3.2μg/ml (STD 4), 4.0μg/ml (STD 5), and 4.8μg/ml (STD 6). 
The quality control samples were prepared at concentrations of 
2.4μg/ml (LQC), 3.2μg/ml (MQC) and 4.0μg/ml (HQC). 
Sample preparation and extraction 
Deferasirox from the plasma was extracted using protein 
precipitation extraction technique. Aliquot of 490μl plasma was 
taken into microcentrifuge tubes and added 10 μl of spiking solution 
then vortexed to mix the contents. Deferasirox is extracted by using 
acetonitrile as a precipitating solvent. Vortexed for 30 sec then the 
solution was centrifuged at 4˚C, 15000rpm for 10 min. The 
supernatant is taken and injected to HPLC. 
HPLC method 
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50:50 10.3 0.7804 523.0 5.3 TP<2000 
55:45 6.7 0.958 2371.3 6.3 Bad peak shape 
60:40 4.3 1.1316 2633.3 3.8 Capacity factor, therapeutic plates, tailing factor within accepted 
range  
(C18 Column, at 1 ml/min flow rate, detection wavelength is 248 nm, mobile phase ratio containing ACN: Buffer (pH-3) respectively)  
 
Method validation  
The method performance was evaluated for selectivity, accuracy, 
precision, linearity, and stability during various stress conditions 
including bench top stability, freeze thaw stability, stability of stock 
solutions etc. and recovery [11].  
Linearity 
Calibration curves were constructed using linear regression (with the 
weighting of 1/x2) within the range of 0.8-4.8μg/ml of deferasirox.  
Recovery 
Recovery of analyte was evaluated by comparing the response of 
deferasirox in three quality control samples (LQC, MQC and HQC) 
with the response of deferasirox in equivalent aqueous solutions.  
Precision and accuracy 
For precision and accuracy studies, samples of three concentration 
levels were prepared as low (LQC), medium (MQC) and high (HQC) 
quality controls, corresponding to 2.4, 3.2 and 4.0μg/ml respectively 
with three replicates each. Precision was evaluated with within and 
between batches. 
Stability studies  
The stability of deferasirox in solutions and plasma samples was 
evaluated during method validation. Deferasirox stability was 
evaluated using two concentration levels (low and high quality 
control, corresponding to 2.4 and 4.0μg/ml respectively). The 
stability of deferasirox was evaluated in plasma samples kept at 
freezer and after being stressed to 3 freeze-thawing cycles (24 
hours each cycle). All samples described above were compared 
to freshly prepared deferasirox samples at the same 
concentration level.  
RESULTS AND DISCUSSION 
Chromatographic Optimization 
A RP-HPLC method was developed for deferasirox, which can be 
conveniently employed for routine analysis in biological fluids. The 
chromatographic conditions were optimized in order to provide a 
good performance of the assay. The mobile phase for drug was 
selected based on its polarity. Different trials were taken and the 
final optimized mobile phase is listed in table 1. The retention time 
of deferasirox was 4.3 min. The chromatogram of deferasirox in 
plasma has been shown in fig. 2. The method is validated as per 
regulatory guidelines.  
Selectivity  
The described method used reversed-phase HPLC for separation of 
deferasirox was shown to be selective. No interfering peaks were 
observed with the same retention time of the analyte when different 
plasma samples were analysed. Fig. 1, fig.2 and fig.3 represent the 
chromatograms of blank plasma sample, plasma sample spiked with 
drug and overlain chromatogram of blank plasma and spiked plasma 
respectively. 
Linearity  
Linearity was demonstrated from 0.8-4.8μg/ml. fig. 4 shows 
calibration curve of deferasirox. The calibration curve includes 6 
calibration standards which are distributed throughout the 
calibration range. Correlation coefficient was demonstrated for the 
evaluation of goodness fit. The average correlation coefficient was 
found to be 0.9914 with goodness of fit.  
Accuracy and precision  
Accuracy and precision were evaluated by analyzing 3 batches. Each 
batch consists of three replicates of LQC, MQC and HQC. Precision 
was evaluated both within and between batches. The within and 
between batch precision and accuracy of the method for each 
deferasirox concentration levels (2.4, 3.2 and 4.0μg/ml) are 
represented in table 2. The mean accuracy for each concentration 
level ranged from 100.6 to 102.3 and the mean precision for each 
concentration level ranged from 0.835 to 2.0%.  
Recovery  
The recovery was evaluated by comparing response of extracted and 
unextracted samples. Extracted samples include three replicates of 
extracted LQC, MQC and HQC samples. Unextracted samples 
included the aqueous solutions equivalent to extracted samples. The 
mean recovery for deferasirox in plasma was ranged from 90.3 to 
92.2% for the low, medium and high quality control samples 
represented in table 3. 
 
 




Fig. 2: Chromatogram of Deferasirox (4.8 µg/ml) in optimized 
chromatographic conditions 
 
Stability studies  
Stability studies were performed to evaluate the stability of 
deferasirox both in aqueous solution and in plasma after exposing to 
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various stress conditions. The stability studies performed include 
stock solution stability, bench top stability in plasma and freeze 
thaw stability in plasma. All Stability evaluations were performed as 
per regulatory guidelines.  
 
 
Fig. 3: Overlain chromatograms of blank plasma and spiked 
plasma 
Deferasirox stock solution (1 mg/ml) remained stable when stored 
at room temperature for 6 hr. Deferasirox was stable in plasma 
samples when store at room temperature for 6 hours. Deferasirox 
was found to be stable for three freeze and thaw cycles. 
 
 
Fig. 4: Calibration curve of deferasirox in plasma
 






Within batch Between batch 
2.4 102.3 2.0 1.4 
3.2 101.2 0.8 1.2 
4.8 100.6 0.9 0.9 
(The % mean accuracy for all QC samples should be in the range of 85.00-115.00%. The % CV for all QC samples should be within 15.00 %.)  
 
Table 3: Recovery result of deferasirox from plasma 





Table 4: Validation parameters of deferasirox by HPLC method 
S. No. Parameters Results 
1. Selectivity Pass 
2. System suitability Pass 





6. Recovery Pass 
7. Short term stock stability 6 Hr 
8. Bench top stability 6 Hr 
9. Freeze and thaw stability Pass (3 cycles) 
 
CONCLUSION 
In the present work, a rapid, sensitive, specific, precise and accurate 
bioanalytical method for deferasirox in human plasma has been 
developed and validated with a larger calibration curve range (i.e. 
0.8 to 4.8µg/ml) using high performance liquid chromatography 
which can be used for routine drug analysis and bioanalysis. 
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